Shareholders that lost money on Metagenomi, Inc. (MGX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

Core Viewpoint - Metagenomi, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its initial public offering and subsequent termination of a collaboration with Moderna [1][2][3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased shares during Metagenomi's IPO from February 9 to 13, 2024 [2]. - Metagenomi's IPO involved selling 6.25 million shares at a price of $15 per share [3]. - The company claimed a significant partnership with Moderna, which was critical to its business model, but this partnership was terminated on May 1, 2024, leading to a decline in stock price from $7.04 to $6.17 per share [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant period have until November 25, 2024, to request appointment as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs for class members [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].